User:James Bahng/sandbox 1
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
== Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor == | == Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor == | ||
- | <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> | ||
- | + | <StructureSection load='1hyo' size='340' side='right' caption='Caption for this structure' scene=''> | |
- | < | + | |
- | + | 1HYO is an EC 3.7.1.2 hydrolase involved in the final step of the Phe/Tyr catabolic pathway, and <scene name='58/581360/Ligand_bound/1'>binds to Fumarylacetoacetate</scene> producing [[http://ec.asm.org/content/6/3/514/F1.large.jpg Fumarate and Acetoacetate]]. | |
- | + | ||
- | + | The mechanism is not well understood, but is hypothesized that His-133 activates a nucleophilic water, which attacks the δ carbon, leading to cleavage. The resultant tetrahedral alkoxy transition state are stabilized by | |
Line 14: | Line 11: | ||
Mutations in 1HYO are responsible for hereditary tyrosemia Type I, a serious metabolic disease resulting in chronic inflammation of the liver and neuronal damage. It is in the same metabolic pathway as Phenylketonuria (PKU) in infants, and is treated similarly with strict dietary control and pharmacological inhibition of Phenylalanine hydroxylase, the key first enzyme in the degradation pathway. | Mutations in 1HYO are responsible for hereditary tyrosemia Type I, a serious metabolic disease resulting in chronic inflammation of the liver and neuronal damage. It is in the same metabolic pathway as Phenylketonuria (PKU) in infants, and is treated similarly with strict dietary control and pharmacological inhibition of Phenylalanine hydroxylase, the key first enzyme in the degradation pathway. | ||
+ | In very serious acute cases, double liver/kidney transplant may be considered as an option as well. | ||
== Relevance == | == Relevance == | ||
Revision as of 04:14, 1 April 2014
Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor
|